TBI-2001

N/A

Report date: 2023/08/01 20:00:44

Base Information

Drug NameTBI-2001
Drug Alias NameCD19·JAK/STAT·CARAutologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T LymphocytesTBI-2001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Health Network (Uhn)Takara Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakara Bio IncUniversity Health Network (Uhn)
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A